Zsolt P. Harsanyi
Chairman of the Board of Directors
N-Gene Company
Hungary
Biography
Dr. Harsanyi has served as a director at Emergent BioSolutions, Inc., Rockville, MD, USA since August 2004. Dr. Harsanyi has served as chief executive officer and chairman of the board of directors of Exponential Biotherapies Inc., a private biotechnology company, from December 2004 to 2010. Dr. Harsanyi was President of Porton International (“Porton”), a pharmaceutical and vaccine company based in Washington, D.C. and in London, U.K.. Before its acquisition by Ipsen, the company manufactured Dysport™, Erwinase, HyateC, and out-licensed Kogenate™ to Bayer Pharmaceuticals. In 1998 Dr. Harsanyi founded Dynport Vaccine Company with DynCorp (Reston, Virginia) and was subsequently awarded a United States Department of Defense vaccine contract of $322 million. Prior to joining Porton, Dr. Harsanyi was Vice-President of Corporate Finance at E.F. Hutton, Inc., with responsibility for assessing and financing biotechnology companies. From 1979 to 1981, Dr. Harsanyi directed the first major assessment of biotechnology for the U.S. Congress’s Office of Technology Assessment, namely, Impacts of Applied Genetics: Microorganisms, Plants and Animals. He served, concurrently, as an adviser to the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Dr. Harsanyi has contributed chapters to several books and is the author of Genetic Prophecy: Beyond the Double Helix. From 1970 to 1979, he served on the faculty of Cornell University Medical College and conducted research in microbial genetics and infectious diseases, and was a recipient of the Andrew W. Mellon Teacher-Scientist Award. In addition to his responsibilities at EBI, Dr. Harsanyi was a trustee of The Immune Disease Institute, an affiliate of Harvard Medical School, now a part of Boston’s Children’s Hospital. He also serves on the Board of Emergent BioSolutions, Inc., a biopharmaceutical company listed on the New York Stock Exchange, where he serves as the Chairman of the Audit Committee. Currently, he also serves as an independent director of Druggability Technologies Holdings, Ltd. Dr. Harsanyi received his B.A. degree from Amherst College and his Ph.D. degree from the Albert Einstein College of Medicine in New York City.
Research Interest
Genetics
